Who
Mansoor Raza Mirza
Director
Company insider
Files Form 4 as: Director, Sera Prognostics; Chief Medical Officer, Acrivon Therapeutics; Director, Karyopharm Therapeutics.
In numbers
- Trades disclosed
- 132
- Buys
- 0
- Sells
- 41
- Bought
- $0
- Sold
- $2.6M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 18 Dec 2013
- Last trade
- 10 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —22,426 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —1,771 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —34,494 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —34,494 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,725 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera Prognosticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,725 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —22,426 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Code A | —1,771 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —38,817 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | ACRV Acrivon TherapeuticsBiotechnology | SEC FORM 4 Code A | —38,817 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —174,068 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —174,068 at $0.00 | filing |
| 5 Dec 2025filed 5 Dec 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $891292 at $3.05 | filing |
| 5 Nov 2025filed 6 Nov 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $672221 at $3.04 | filing |
| 6 Oct 2025filed 6 Oct 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $717227 at $3.16 | filing |
| 1 Oct 2025filed 3 Oct 2025 | ACRV Acrivon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 5 Sep 2025filed 5 Sep 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $744222 at $3.35 | filing |
| 5 Aug 2025filed 5 Aug 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $563225 at $2.50 | filing |
| 7 Jul 2025filed 8 Jul 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $552234 at $2.36 | filing |
| 6 Jun 2025filed 6 Jun 2025 | SERA Sera PrognosticsDiagnostics & Labs | SEC FORM 4 Sold | $169107 at $1.58 | filing |
News
Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head ReviewSERA · themarketsdaily.com · 18 Oct 2026Insider Selling: Sera Prognostics (NASDAQ:SERA) Insider Sells 8,024 Shares of Company StockSERA · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Mansoor Raza Mirza; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.